All In Biotech

Drug Trial Radar · NCT05513586

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

15

Actual

Start

Sep 13, 2022

Primary completion

Oct 30, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Aug 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to check side effect from the study treatment with TAK-771 in long term. Participants can have taken part in the previous study TAK-771-3004 (NCT05150340). For those who can take part, the participants will receive injections of TAK-771 after the end of the previous study. The participants will be treated with TAK-771 for totally 3 years. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug.

Conditions

  • Primary Immunodeficiency Diseases (PID)

Interventions

  • TAK-771Drug

    Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From start of study drug administration up to end of study (up to 3.1 years)
  2. Percentage of Participants Who Developed Anti-rHuPH20 Binding Antibody Titers of >=1:160 and Neutralizing Antibodies to rHuPH20Time frame: From start of study drug administration up to end of study (up to 3.1 years)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Kyushu University Hospital

    Fukuoka, Japan

  • Gifu University Hospital

    Gifu, Japan

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Saitama Prefectual Children's Medical Center

    Saitama, Japan

  • Shizuoka Childrens Hospital

    Shizuoka, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • Hospital of University of Occupational and Environmental Health

    Kitakyushu, Fukuoka, Japan

  • Kanagawa Children's Medical Center

    Yokohama, Kanagawa, Japan

  • Tokyo Medical Dental University Hospital

    Bunkyo-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.